CTMX
CytomX Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.76
−2.13%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.09
- Revenue estimate
- $10.4M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.09
- EPS estimate
- -$0.08
- Revenue actual
- $1.4M
- Revenue estimate
- $12.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -62.2%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $13
- PT range
- $11 – $14
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.08 | -$0.09 | Miss -16.76% | $1.4M |
| May 7, 2026 | -$0.14 | -$0.10 | Beat 28.57% | $10.3M |
| Mar 16, 2026 | -$0.09 | -$0.22 | Miss -135.70% | $663.0K |
| Nov 6, 2025 | -$0.04 | -$0.09 | Miss -125.00% | $6.0M |
| Aug 7, 2025 | -$0.06 | -$0.00 | Beat 98.02% | $18.7M |
| Mar 6, 2025 | -$0.23 | $0.22 | Beat 195.65% | $38.1M |
| Nov 7, 2024 | -$0.17 | $0.07 | Beat 141.18% | $33.4M |
| Mar 11, 2024 | $0.00 | $0.01 | Beat 134.74% | $26.6M |
| Aug 4, 2022 | -$0.36 | -$0.37 | Miss -2.78% | $18.2M |
| May 5, 2022 | -$0.35 | -$0.37 | Miss -5.71% | $17.1M |
| Mar 1, 2022 | -$0.25 | -$0.40 | Miss -60.00% | $19.7M |
| Nov 4, 2021 | -$0.30 | -$0.35 | Miss -16.67% | $17.6M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026